...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Salvage Options for Eradication of Helicobacter pylori During Tetracydine Backorder
【24h】

Salvage Options for Eradication of Helicobacter pylori During Tetracydine Backorder

机译：Tetracydine补货期间根除幽门螺杆菌的救助选择

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To review salvage options for Helicobacter pylori eradication regimens during a tetracydine backorder for patients with triple-therapy failure.Data Sources: A search of PubMed (1980-June 2012) was conducted using a combination of the terms H. pylori or Helicobacter pylori, salvage therapy, and eradication or treatment as text word searches.Study Selection and Data Extraction: Clinical trials and meta-analyses published in English were included. A manual review of the bibliographies of available literature was conducted and relevant articles were reviewed for inclusion.Data Synthesis: Treatment of H. pylori consists of a triple-drug regimen that includes a proton pump inhibitor (PPI), amoxicillin or metronidazole, and clarithromycin. Failure with this therapy is becoming increasingly common due to macrolide resistance. Upon failure with this regimen, it is recommended that a quadruple regimen with bismuth subsalicylate, metronidazole, tetracydine, and a histamine2 receptor antagonist or a PPI be used. Recent backorders by the 2 manufacturers for tetracydine restrict the use of this regimen. Options that can be considered include minocycline or doxycycline in place of tetracydine, levofloxacin- or moxifloxadn-based regimens, a tinidazole-based regimen, or a rifabutin-based regimen. This article includes a review of 1 study each of minocycline and doxycycline, 5 levofloxacin studies (including meta-analyses), 2 moxifloxacin studies, 1 rifabutin study, and 1 tinidazole study. There are limited data with other tetracyclines; however, given the resistance to quinolones in some areas and possible drug interactions and adverse effects from rifabutin, minocycline or doxycycline regimens may be a better second-line regimen option.Conclusions: Given the current tetracydine shortage, minocycline and doxycycline are options to be considered in patients with a macrolide-based treatment failure. Fluoroquinolones may be an option for patients who have not received these drugs for other indications in the recent past or in areas where resistance is low.
机译：目的：回顾三联疗法失败的患者在四环素延期交货期间幽门螺杆菌根除方案的挽救选择。数据来源：对PubMed（1980-2012年6月）的搜索结合使用了幽门螺杆菌或幽门螺杆菌，挽救疗法以及根除或治疗等文本检索词。研究选择和数据提取：包括以英语发表的临床试验和荟萃分析。资料综述：幽门螺杆菌的治疗由三重药物疗法组成，其中包括质子泵抑制剂（PPI），阿莫西林或甲硝唑和克拉霉素。由于大环内酯类药物的耐药性，这种疗法的失败变得越来越普遍。如果该方案失败，建议使用四联方案，其中包括水杨酸铋，甲硝唑，四环素和组胺2受体拮抗剂或PPI。 2家生产商最近对四环素的缺货限制了该方案的使用。可以考虑的选择包括用米诺环素或强力霉素代替四环素，基于左氧氟沙星或莫西沙星的方案，基于替硝唑的方案或基于利福布汀的方案。本文包括对米诺环素和强力霉素各自的1项研究，5项左氧氟沙星研究（包括荟萃分析），2项莫西沙星研究，1项利福布汀研究和1项替硝唑研究的评论。其他四环素的数据有限。然而，考虑到某些地区对喹诺酮类药物的耐药性以及利福布汀，米诺环素或多西环素方案可能产生的药物相互作用和不良反应，可能是更好的二线方案。结论：鉴于当前四环素短缺，应考虑使用米诺环素和多西环素大环内酯类药物治疗失败的患者。氟喹诺酮类药物可能是最近一段时间或耐药性较低地区未因其他适应症而接受这些药物的患者的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号